Press Release : Addex Announces Filing of Registration Statement for Proposed Public Offering of Securities

   Geneva, Switzerland, December 14, 2020 -- Addex Therapeutics 
https://www.globenewswire.com/Tracker?data=t-xEjKgmoAz5nmlIu6rq_EnbExaPpynsitjTDauBnGczHHgbOnAG6l5T6oy_aLOiQDWVibPpTG4rQLglKb-PD7d1R3y92av2hZBiQMpOy34= 
Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical 
company pioneering allosteric modulation-based drug discovery and 
development announced today that it has filed a registration statement 
with the U.S. Securities and Exchange Commission (SEC) for a proposed 
underwritten public offering of shares, including those to be settled in 
the form of American Depositary Shares (ADSs). Each ADS represents the 
right to receive six shares of Addex.  The terms of the offering have 
not been determined, and the offering is subject to market and other 
conditions, and there can be no assurance as to whether or when the 
offering may be completed. The Company will be concurrently offering the 
shares in Europe (other than Switzerland) in a private placement to 
qualified investors, and in Switzerland through private placements. 
 
   H.C. Wainwright & Co. is acting as sole book-running manager for the 
offering. 
 
   The proposed offering will be made only by means of a prospectus. Once 
available, an electronic copy of the preliminary prospectus relating to, 
and describing the terms of, the offering may be obtained from H.C. 
Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, 
by telephone at [phone] or e-mail at 
https://www.globenewswire.com/Tracker?data=M9LtMTc-VGj11Okhl5DHJ6D7fQ4q-tLfZEh5Tp73zurBnn9LyfG-CvZO-s6REFT2V791u5-gEjnm2C8lHiOr4dGmafsLJ2XMpiMlh7tEmyk= 
[e-mail] or on the SEC's website. 
 
   A registration statement on Form F-1 relating to the proposed sale of 
these securities has been filed with the SEC but has not yet become 
effective. These securities may not be sold, nor may offers to buy be 
accepted, prior to the time the registration statement becomes 
effective. This press release shall not constitute an offer to sell or 
the solicitation of an offer to buy these securities, nor shall there be 
any sale of these securities in any state or jurisdiction in which such 
offer, solicitation or sale would be unlawful prior to registration or 
qualification under the securities laws of any such state or 
jurisdiction. There is no intention or permission to publicly offer, 
solicit, sell or advertise, directly or indirectly, any securities of 
Addex Therapeutics Ltd in or into Switzerland within the meaning of the 
Swiss Financial Services Act ("FinSA"). Neither this document nor any 
other offering or marketing material relating to these securities, such 
as the shares, constitutes or will constitute a prospectus pursuant to 
the FinSA, and neither this document nor any other offering or marketing 
material relating to the shares constitutes a prospectus pursuant to the 
FinSA, and neither this document nor any other offering or marketing 
material relating to the shares may be publicly distributed or otherwise 
made publicly available in Switzerland. 
 
   About Addex Therapeutics: 
 
   https://www.globenewswire.com/Tracker?data=t-xEjKgmoAz5nmlIu6rq_C9Gjjx3jgknw7Bgtd3o2dWsas6RVDkI0e9gE_WgV-V0bmLnDFoBxSMjQeB2DW1D2lS35LRN_5J-2uU59Qj4H31GDekeSBiPBMRKGF4QqkH3 
Addex Therapeutics is a clinical-stage pharmaceutical company focused on 
the development and commercialization of an emerging class of novel 
orally available small molecule drugs known as allosteric modulators for 
neurological disorders. Allosteric modulators offer several potential 
advantages over conventional non-allosteric molecules and may offer an 
improved therapeutic approach to conventional "orthosteric" small 
molecule or biological drugs. Addex's allosteric modulator drug 
discovery platform targets receptors and other proteins that are 
recognized as essential for therapeutic intervention. Addex's lead drug 
candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is 
poised to start  a pivotal registration clinical trial for Parkinson's 
disease levodopa induced dyskinesia (PD-LID) in 2021. Addex is also 
investigating dipraglurant's therapeutic use in blepharospasm (a type of 
dystonia), for which a clinical trial is expected to be initiated in 
2021. Addex's third clinical program, ADX71149 (mGlu2 positive 
allosteric modulator or PAM), developed in collaboration with Janssen 
Pharmaceuticals, Inc, is scheduled to enter a phase 2a proof of concept 
clinical study for the treatment of epilepsy in 2021. Addex's GABAB PAM 
program has been licensed to Indivior PLC for the treatment of 
addiction. Preclinical programs include GABA(B)  PAM for CMT1A, mGlu7 
NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for 
Parkinson's disease and mGlu3 PAM for neurodegenerative disorders. 
 
   Press Contacts: 
 
 
 
 
Tim Dyer                                                          Mike Sinclair 
 Chief Executive Officer                                           Partner, Halsin Partners 
 Telephone: [phone]                                       [phone] 
 Email: mailto:[e-mail] [e-mail]   mailto:[e-mail] [e-mail] 
----------------------------------------------------------------  ------------------------------------------------- 
 
   Forward Looking Statements: 
 
   Statements in this announcement concerning the timing and terms of the 
anticipated offering of the Company's securities are forward-looking 
statements, which are subject to risks and uncertainties, including 
those risks described in the Company's Annual Report on Form 20-F filed 
with the SEC on April 27, 2020, as well as market conditions and 
regulatory review. 
 
 
 
 

(END) Dow Jones Newswires

December 14, 2020 12:22 ET (17:22 GMT)